Navigation Links
Auspex Pharmaceuticals Receives U.S. Patent on Novel JAK Inhibitor SD-900
Date:11/15/2012

LA JOLLA, Calif., Nov. 15, 2012 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. today announced that it has been granted U.S. Patent No. 8,299,084 covering the company's novel JAK kinase inhibitor SD-900, a deuterium-substituted analogue of tofacitinib.

"The issuance of a composition-of-matter patent for SD-900 is strong validation of Auspex's technological approach to the creation of important new drugs," said Lawrence C. Fritz, Ph.D., President and Chief Executive Officer of Auspex. "We believe that SD-900 can emerge as an important drug in the JAK inhibitor space, combining the efficacy of tofacitinib with improved metabolic properties." 

The JAK kinases have emerged as important targets for drugs to treat autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and psoriasis as well as for the treatment of certain types of cancer. The JAK inhibitor drug tofacitinib was recently approved by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis and is also in clinical development for additional autoimmune diseases. Auspex believes that SD-900 will retain precisely the intrinsic pharmacological activity of tofacitinib but improve its pharmacokinetics. These properties may allow SD-900 to provide the efficacy of tofacitinib but at a reduced dose, and may also promote the development of a once-a-day JAK inhibitor for use in treating autoimmune diseases.

Auspex's lead compound, SD-809, also incorporates deuterium into its structure and is entering phase 3 clinical trials for the treatment of hyperkinetic movement disorders, specifically, the chorea associated with Huntington's disease.

About SD-900

SD-900 is a novel "JAK inhibitor", a small molecule inhibitor of the Janus Kinase enzyme family.  It is a specific deuterium-substituted analogue of tofacitinib. Deuterium is a safe, naturally occurring, non-radioactive form of hydrogen. Because the substitution of deuterium for hydrogen does not change the shape of a molecule or its electronic structure, it does not change the binding properties of a drug. However, in certain cases these substitutions can have a beneficial effect on increasing the half-life of the drug. Because of these properties of deuterium, Auspex believes that SD-900 will have equivalent efficacy to tofacitinib but with the prospect of improved pharmaceutical properties.

About Auspex Pharmaceuticals

Auspex Pharmaceuticals is a privately held biopharmaceutical company located in La Jolla, California.  The company is a pioneer in the use of deuterium in medicinal chemistry, and its most advanced program is focused on the treatment of hyperkinetic movement disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia.  Its lead compound, SD-809, is a novel inhibitor of the vesicular monoamine transporter 2 (VMAT-2). This drug offers the potential for significant advantages over existing therapies including improved safety, reduced drug-drug interactions, and less frequent dosing. SD-809 is expected to enter phase 3 clinical testing in 2013. Auspex is also exploiting its deuterium chemistry approach to optimize drugs in several additional therapeutic areas. Included in the Auspex portfolio are SD-900, a JAK kinase inhibitor for the treatment of autoimmune diseases, SD-560 for the treatment of fibrotic diseases, as well as other compounds. For more information on Auspex, please visit the company's web site at http://www.auspexpharma.com.


'/>"/>
SOURCE Auspex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals To Host Third Quarter Investor Call on Wednesday, November 28th
2. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
3. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
4. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
5. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Frost & Sullivan: Lack of Proper Price Regulation for Pharmaceuticals
7. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
8. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
9. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
10. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):